Trogenix

Transforming cancer treatment paradigms

Founded 2023 · $107.5M raised

Employees
1–10
Founded
2023
Business Model
B2B
Total Funding
$107.5M
Last Round
$95.0M Series AOct 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Trogenix is a cancer therapy company pioneering precision genetic medicines using proprietary Synthetic Super-Enhancer (SSE) technology delivered via AAV vectors. Its Odysseus platform selectively targets aggressive solid tumours — beginning with glioblastoma — by leveraging transcription factors unique to cancer cells to trigger immune-mediated tumour destruction. The company aims to deliver curative, one-and-done therapies for patients with devastating cancers.

Summary

Trogenix is a Biotech company, founded in 2023. It has raised $107.5M in total across 2 rounds, most recently a $95.0M Series A round in Oct 2025. Investors include IQ Capital Partners, 4BIO Capital and Cancer Research Horizons.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AOct 2025
$95.0M

Sign up to see all 2 events

Funding: Seed through Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Trogenix on Indexed.vc
<a href="https://indexed.vc/companies/trogenix"><img src="https://indexed.vc/api/badge/company/trogenix" alt="Trogenix on Indexed.vc" width="260" height="76" /></a>